NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles. The technology enables the synthesis of new-generation nanoparticles with a high degree of size and morphological control, as well as tunable surface charge and chemistry. These properties enable the production of biodegradable nanoparticles that display improved physiological stability, longer blood retention times, low acute toxicity and low immunogenicity. The tunable surface properties allow several types of functionality to be easily incorporated for imaging (optical, magnetic and nuclear), targeting and controlled delivery of cargo. This is synergistic with NPH’s materials science platform.

“We are pleased to have licensed this technology. This further illustrates our ability and commitment to selectively add important technologies to our platform. This technology, developed by Dr. Tseng along with several other collaborators at UCLA has profound implications for drug delivery, gene transfection centering on siRNA, and companion diagnostics,” stated Joseph A. Boystak, Chairman & Co-CEO.

“This technology should facilitate our ability to collaborate with a variety of corporate partners, research institutions and other academic researchers,” said Michael Flesch, Vice Chairman & Co-CEO.

“I am pleased that my interaction and involvement with NPH will accelerate the development of the supramolecular nanoparticle systems toward applications in biology and medicine,” said Dr. Tseng, Associate Professor, Molecular and Medical Pharmacology at UCLA.


NanoPacific Holdings, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New dry powder aerosol COVID-19 vaccine shows promise against multiple virus strains